IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

  From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

  Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

- **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please scan the QR code or visit www.repatha.com/PI for Repatha® full Prescribing Information.

Repatha® (evolocumab) injection 140 mg/mL

Helping patients **START AND STAY ON REPATHA®**

Your Repatha® patients may have **QUESTIONS AFTER LEAVING YOUR OFFICE**

Amgen® Nurse Partners are available by live video or phone to:

1. **Provide one-on-one supplemental injection support** to help patients get more comfortable injecting Repatha® in the comfort of their own home
2. **Answer frequently asked questions** on topics like storage, disposal and traveling with Repatha®
3. **Provide personalized touchpoints** throughout the first 6 months of therapy to help build patient confidence and to share important patient resources.

*Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient's treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Amgen® Nurse Partners are available in multiple languages
[Monday - Friday from **8am - 8pm ET]**

1-844-REPATHA

Online injection resources available at **Repathainjection.com** or by scanning this **QR code**:

IMPORTANT SAFETY INFORMATION, CONTINUED

Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please see additional Important Safety Information throughout.

References: 1. Data on file, Amgen; [1]; 2023. **2.** CoverMyMeds. Complete PA requests up to 3x faster. https://www.covermymeds.com/main/solutions/provider/. Accessed September 15, 2022. **3.** Data on file, Amgen; [Repatha ePA Turnaround Times 01 Jun 2021 through 30 Jun 2022 from CoverMyMeds, August 2022]. **4.** Data on file, Amgen; [2]; 2023.

AMGEN®

Repatha® (evolocumab) injection 140 mg/mL

Your guide to help patients **start and stay on Repatha®**

- The doctor has identified the appropriate patient and prescribed Repatha®, now it's time to ensure you have the correct documentation to start the Prior Authorization Process
- Use the tools and support outlined here to help you and your office
- Help your patients learn about Amgen® SupportPlus resources like the **Amgen® Nurse Partner** support and the co-pay card for commercial patients

Repatha® has broad coverage: **9 OUT OF 10** PATIENTS ARE COVERED[1,*]

*Includes commercial, health exchange, Medicaid and Medicare lives. As of April 2023, based on MMIT data. This information is subject to change without notice. For the most up-to-date and complete information regarding the status of Repatha®, please contact the relevant payer directly.

INDICATIONS

Repatha® is indicated:

- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please see additional Important Safety Information throughout.

Repatha® (evolocumab) injection 140 mg/mL

Many plans only require an attestation for prior authorization (PA) of Repatha®. Some plans may still request the submission of clinical documentation with the PA. For those plans, consider including the following:

DIAGNOSIS DETAILS
(such as example diagnosis codes and chart notes)

You may use the QR code to access further information with the Repatha® Coding Guide, including a list of illustrative ICD-10 codes.

HISTORY OF OTHER LIPID-LOWERING TREATMENT
(chart notes)

It may be important to include the current/past treatments, history/intolerance of statins, and other lipid-lowering therapies

RECENT LIPID PANEL WITH DATES
(typically over the last 90 days)

If the patient has tried Repatha®, remember you may also need to include pre- and post-Repatha® LDL-C levels

Repatha® (evolocumab) injection 140 mg/mL

Helping you
WITH RESOURCES TO START THE PRIOR AUTHORIZATION PROCESS

ELECTRONIC PRIOR AUTHORIZATION (ePA) OPTIONS

Submit ePA requests for Repatha® to payers and review determinations in real time by using your ePA-enabled EHR or online portals like CoverMyMeds at no cost

KEY FEATURES OF ePAS

QUICK SUBMISSION

- ePAs prepopulate patient, provider and prescription information from your electronic health record (EHR) or from rejected claims
- ePAs for Repatha® are automatically added to provider PA queues
- With CoverMyMeds, PA requests can be submitted up to 3 times faster than manual PAs, and you can create PA renewals from previously submitted requests.[2]

RECEIVE PA DETERMINATIONS SOONER

For Repatha® ePAs submitted through **CoverMyMeds***

- **~40%** received an instant determination **WITHIN 5 MIN**[3,†]
- **~80%** received a determination within **24 HOURS**[3,†]

AMGEN® ACCESS SPECIALIST (OR AS)

provides access education and support to offices in order to help Repatha® patients access their therapy.

AREAS OF FOCUS

1. Prior authorizations / reauthorizations
2. Appeals process
3. Insurance information / utilization management (UM) criteria
4. Financial support resources
5. General access information / education

HELP IS AVAILABLE IN PERSON OR VIRTUALLY

Speak to your Repatha® representative to obtain your AS contact information. **You can reach out to your AS for help with any of the above.**

*Amgen, the marketer of Repatha®, has entered into a fee-for-service arrangement with CoverMyMeds to provide a differentiated ePA experience after you have chosen to prescribe Repatha®. CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.

†Data from June 1, 2021 through June 30, 2022, measuring time between when a complete ePA is submitted to the health plan and determination is received by the HCP. These statistics are subject to change and are based upon a multitude of factors that can influence turnaround time.

Repatha® (evolocumab) injection 140 mg/mL

Helping patients
START AND STAY ON REPATHA®

Repatha® may **COST YOUR PATIENTS LESS THAN YOU THINK**

MEDICARE

~71% of prescriptions cost patients **$49 OR LESS**[4,*,†]

MEDICAID

99% of prescriptions cost patients **$10 OR LESS**[4,*]

COMMERCIAL

Commercially insured patients **MAY PAY $5 A MONTH**[‡] with the Repatha® Co-pay Card

Have your commercial patients enroll in the Repatha® Co-pay Card by visiting **Repatha.com/enroll** or by **scanning the QR code** on the Repatha® Co-pay Card brochure.

*Based on IQVIA data from 1/2022 – 12/2022 using the respective Medicare or Medicaid data

†The patient's out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in. Medicare Part D drug coverage is divided into four phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.

‡Subject to eligibility criteria and program maximums. Visit www.repatha.com/copay for full terms and conditions.

IMPORTANT SAFETY INFORMATION, CONTINUED

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please see additional Important Safety Information throughout.

Repatha® (evolocumab) injection 140 mg/mL

Your guide to help patients **start and stay on Repatha®**

- The doctor has identified the appropriate patient and prescribed Repatha®, now it's time to ensure you have the correct documentation to start the Prior Authorization Process
- Use the tools and support outlined here to help you and your office
- Help your patients learn about Amgen® SupportPlus resources like the **Amgen® Nurse Partner** support and the co-pay card for commercial patients

Repatha® has broad coverage: **9 OUT OF 10** PATIENTS ARE COVERED[1,*]

*Includes commercial, health exchange, Medicaid and Medicare lives. As of April 2023, based on MMIT data. This information is subject to change without notice. For the most up-to-date and complete information regarding the status of Repatha®, please contact the relevant payer directly.

INDICATIONS

Repatha® is indicated:

• In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization

• As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

IMPORTANT SAFETY INFORMATION

• **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Repatha® (evolocumab) injection 140 mg/mL

Many plans only require an attestation for prior authorization (PA) of Repatha®. Some plans may still request the submission of clinical documentation with the PA. For those plans, consider including the following:

DIAGNOSIS DETAILS
(such as example diagnosis codes and chart notes)

You may use the QR code to access further information with the Repatha® Coding Guide, including a list of illustrative ICD-10 codes.

HISTORY OF OTHER LIPID-LOWERING TREATMENT
(chart notes)

It may be important to include the current/past treatments, history/intolerance of statins, and other lipid-lowering therapies

RECENT LIPID PANEL WITH DATES
(typically over the last 90 days)

If the patient has tried Repatha®, remember you may also need to include pre- and post-Repatha® LDL-C levels

IMPORTANT SAFETY INFORMATION, CONTINUED

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Repatha® (evolocumab) injection 140 mg/mL

IMPORTANT SAFETY INFORMATION

- **Contraindication:** Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

  From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

  Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

- **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please click here for full Prescribing Information.

Repatha® (evolocumab) injection 140 mg/mL

Helping you
WITH RESOURCES TO START THE PRIOR AUTHORIZATION PROCESS

ELECTRONIC PRIOR AUTHORIZATION (ePA) OPTIONS

Submit ePA requests for Repatha® to payers and review determinations in real time by using your ePA-enabled EHR or online portals like CoverMyMeds at no cost

KEY FEATURES OF ePAS

QUICK SUBMISSION

- ePAs prepopulate patient, provider and prescription information from your electronic health record (EHR) or from rejected claims
- ePAs for Repatha® are automatically added to provider PA queues
- With CoverMyMeds, PA requests can be submitted up to 3 times faster than manual PAs, and you can create PA renewals from previously submitted requests.[2]

RECEIVE PA DETERMINATIONS SOONER

For Repatha® ePAs submitted through **CoverMyMeds***

- **~40%** received an instant determination **WITHIN 5 MIN**[3,†]
- **~80%** received a determination within **24 HOURS**[3,†]

AMGEN® ACCESS SPECIALIST (OR AS)

provides access education and support to offices in order to help Repatha® patients access their therapy.

AREAS OF FOCUS

1. Prior authorizations / reauthorizations
2. Appeals process
3. Insurance information / utilization management (UM) criteria
4. Financial support resources
5. General access information / education

HELP IS AVAILABLE **IN PERSON** OR **VIRTUALLY**

Speak to your Repatha® representative to obtain your AS contact information. **You can reach out to your AS for help with any of the above.**

*Amgen, the marketer of Repatha®, has entered into a fee-for-service arrangement with CoverMyMeds to provide a differentiated ePA experience after you have chosen to prescribe Repatha®. CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.

†Data from June 1, 2021 through June 30, 2022, measuring time between when a complete ePA is submitted to the health plan and determination is received by the HCP. These statistics are subject to change and are based upon a multitude of factors that can influence turnaround time.

Repatha® (evolocumab) injection 140 mg/mL

Helping patients
START AND STAY ON REPATHA®

Repatha® may COST YOUR PATIENTS LESS THAN YOU THINK

MEDICARE

~71% of prescriptions cost patients
$49 OR LESS[4,*,†]

MEDICAID

99% of prescriptions cost patients
$10 OR LESS[4,*]

COMMERCIAL

Commercially insured patients
MAY PAY $5 A MONTH[‡]
with the Repatha® Co-pay Card

Have your commercial patients enroll in the Repatha® Co-pay Card by visiting **Repatha.com/enroll** or by **scanning the QR code** on the Repatha® Co-pay Card brochure.

*Based on IQVIA data from 1/2022 – 12/2022 using the respective Medicare or Medicaid data

†The patient's out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in. Medicare Part D drug coverage is divided into four phases, each with a different cost-sharing amount. Those phases are 1) Deductible, 2) Initial coverage, 3) Coverage gap, 4) Catastrophic.

‡Subject to eligibility criteria and program maximums. Visit www.repatha.com/copay for full terms and conditions.

IMPORTANT SAFETY INFORMATION, CONTINUED

Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

Repatha® (evolocumab) injection 140 mg/mL

Helping patients
START AND STAY ON REPATHA®

Your Repatha® patients may have
QUESTIONS AFTER LEAVING YOUR OFFICE

Amgen® Nurse Partners are available by live video or phone to:

1. **Provide one-on-one supplemental injection support** to help patients get more comfortable injecting Repatha® in the comfort of their own home
2. **Answer frequently asked questions** on topics like storage, disposal and traveling with Repatha®
3. **Provide personalized touchpoints** throughout the first 6 months of therapy to help build patient confidence and to share important patient resources.

*Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient's treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Amgen® Nurse Partners are available in multiple languages
[Monday - Friday from **8am - 8pm ET]**

1-844-REPATHA

Online injection resources available at **Repathainjection.com** or by scanning this **QR code:**

IMPORTANT SAFETY INFORMATION, CONTINUED

Adverse Reactions in Primary Hyperlipidemia, continued: From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information.

References: 1. Data on file, Amgen; [1]; 2023. **2.** CoverMyMeds. Complete PA requests up to 3x faster. https://www.covermymeds.com/main/solutions/provider/. Accessed September 15, 2022. **3.** Data on file, Amgen; [Repatha ePA Turnaround Times 01 Jun 2021 through 30 Jun 2022 from CoverMyMeds, August 2022]. **4.** Data on file, Amgen; [2]; 2023.

AMGEN®

Repatha® (evolocumab) injection 140 mg/mL